6864.TWO Anti-Microbial Savior BioteQ Co., Ltd.
- Market cap
- TWD 1.29B
- P/E
- -
- P/B
- 2.98x
- ROE
- -18.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 6864.TWO undervalued?
Graham numberThe Graham number of Anti-Microbial Savior BioteQ Co., Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Anti-Microbial Savior BioteQ Co., Ltd. fundamental analysis
No fundamental analysis for Anti-Microbial Savior BioteQ Co., Ltd. yet.
Anti-Microbial Savior BioteQ Co., Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Anti-Microbial Savior BioteQ Co., Ltd.
Anti-Microbial Savior BioteQ Co., Ltd. focuses on the research and development of pharmaceutical drug products in Taiwan. The company offers PoroVance precision pore engineering and small-molecule drug discovery. Its pipeline products include FORMOSA-1117, antibacterial drug candidate; YUAN-03, antiviral drug candidate; AMS-2140, broad-spectrum antiviral drug candidate; TenTacle, ADC linker-conjugate compound. Anti-Microbial Savior BioteQ Co., Ltd. was founded in 2018 and is…
Full company profileAnti-Microbial Savior BioteQ Co., Ltd. financial statements
Anti-Microbial Savior BioteQ Co., Ltd. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 88.0K | 2.70M | 728K | 612K | 706K |
| Gross Profit | 47.0K | 1.29M | 329K | 144K | 326K |
| Operating Income | -28.3M | -43.4M | -59.9M | -76.5M | -96.0M |
| EBITDA | - | -30.2M | -46.2M | -63.7M | -82.4M |
| Net Income | -22.4M | -31.7M | -51.8M | -74.5M | -93.6M |
| EPS | -0.87 | -1.24 | -2.02 | -2.27 | -2.48 |
| Balance Sheet | |||||
| Total Assets | 221M | 182M | 128M | 248M | 520M |
| Total Liabilities | 17.2M | 9.77M | 6.99M | 10.9M | 9.92M |
| Shareholders' Equity | 204M | 172M | 121M | 237M | 510M |
| Cash & Short-term Investments | 167M | 131M | 78.4M | 194M | 466M |
| Cash Flow | |||||
| Operating Cash Flow | -20.1M | -30.7M | -48.3M | -64.1M | -77.7M |
| Capital Expenditure | 3.29M | 7.74M | 1.52M | 8.37M | 6.84M |
| Free Cash Flow | -23.4M | -38.4M | -49.8M | -72.5M | -84.6M |
| Ratios | |||||
| ROE | -11.0% | -18.4% | -42.8% | -31.4% | -18.3% |
| ROA | -10.1% | -17.4% | -40.4% | -30.0% | -18.0% |
| Net Profit Margin | -25,398.9% | -1,176.8% | -7,112.9% | -12,176.0% | -13,257.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Anti-Microbial Savior BioteQ Co., Ltd. dividends
Anti-Microbial Savior BioteQ Co., Ltd. has not paid dividends in the last 5 fiscal years.
Who owns Anti-Microbial Savior BioteQ Co., Ltd.
Ownership data of Anti-Microbial Savior BioteQ Co., Ltd. is not available yet.
Anti-Microbial Savior BioteQ Co., Ltd. company profile
- Company name
- Anti-Microbial Savior BioteQ Co., Ltd.
- Ticker
- 6864.TWO
- ISIN
- TW0006864002
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 33
- Fiscal year end
- December
- Address
- No. 6, Siwei 3rd Rd., Kaohsiung, Taiwan, 802
- Phone
- 886 7 223 7578
- Website
- ams-bioteq.com
About Anti-Microbial Savior BioteQ Co., Ltd.
Anti-Microbial Savior BioteQ Co., Ltd. focuses on the research and development of pharmaceutical drug products in Taiwan. The company offers PoroVance precision pore engineering and small-molecule drug discovery. Its pipeline products include FORMOSA-1117, antibacterial drug candidate; YUAN-03, antiviral drug candidate; AMS-2140, broad-spectrum antiviral drug candidate; TenTacle, ADC linker-conjugate compound. Anti-Microbial Savior BioteQ Co., Ltd. was founded in 2018 and is headquartered in Kaohsiung, Taiwan.
Anti-Microbial Savior BioteQ Co., Ltd. management
5- Dr. George TsaiGM & Chairman
- Dr. Zhida WeiCEO & Director
- Mr. Yi-Wei ZhangPresident
- Mr. Nicolas LiuHead of Finance Management Department
- Mr. Felix TsaiChief Business Officer